Advasure
Adjuvanted vaccine against classical swine fever
Table of contents
Overview
The marketing authorisation for Advasure has been withdrawn at the request of the marketing authorisation holder.
Authorisation details
| Product details | |
|---|---|
| Name |
Advasure
|
| Agency product number |
EMEA/V/C/000053
|
| Active substance |
E2 glycoprotein of classical swine fever virus
|
| International non-proprietary name (INN) or common name |
Adjuvanted vaccine against classical swine fever
|
| Species |
Pigs
|
| Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI09AA06
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Pfizer Limited
|
| Revision |
5
|
| Date of issue of marketing authorisation valid throughout the European Union |
02/02/2001
|
| Contact address |
Ramsgate Road
Sandwich Kent CT13 9NJ United Kingdom |
Product information
06/02/2008 Advasure - EMEA/V/C/000053 -
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Immunologicals for suidae
Therapeutic indication
Active immunisation of pigs, over the age of 2 weeks, against Classical Swine Fever (CSF), to prevent
mortality, reduce clinical signs of the disease and the excretion of field virus.
The onset of protection is 2 weeks.
The duration of protection is 6 months.